Sillajen announced the presentation of a poster detailing the clinical study of BAL0891, an anticancer drug currently undergoing phase I clinical trials in the U.S. and Korea, at the 2023 EORTC-NCI-AACR Symposium in Boston. The symposium, a collaborative effort by the European Organization for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR), took place from last Wednesday to Sunday.
BAL0891, a Mitotic Checkpoint Inhibitor-family drug licensed from Basilea, Switzerland, in September last year, functions as a dual kinase inhibitor targeting threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). The poster presented at the symposium provided insights into BAL0891's mechanism of action, preclinical outcomes, and an overview of the ongoing clinical trials. Patient enrollment for these trials began in the U.S. in February and in Korea in July.
A Sillajen official emphasized the significance of the drug's presentation at such a prestigious conference, stating, "A world-renowned conference has adopted and presented a research overview of a drug that has now begun clinical trials, meaning that the value of the drug and the expectations for the research are great."
